Replies to post #111654 on Biotech Values

[DewDiligence]

…that leaves only immunogenicity and supply chain issues as obstacles for amphastar, and presumably only immunogenicity for teva

No, it also leaves reverse engineering of the Lovenox manufacturing process, which may require use of analytical tools patented by MNTA.